Effects of Macular Ischemia and Early Treatment on Visual Outcome in Branch Retinal Vein Occlusion
Journal of the Korean Ophthalmological Society
;
: 209-215, 2014.
Artigo
em Coreano
| WPRIM
| ID: wpr-90234
ABSTRACT
PURPOSE:
To evaluate the effects of macular ischemia and early treatment on the visual outcomes of patients with branch retinal vein occlusion (BRVO).METHODS:
This study retrospectively reviewed the records of 42 patients who were treated with an intravitreal bevacizumab injection for BRVO, repeated 3 times at 6-week intervals and were whose data available for a follow-up period of at least 4 years. Best-corrected visual acuity (BCVA) and optical coherence tomography (OCT) results before treatment and at 6, 12, 24, 36 and 48 months after the 3 serial injections, were measured. We assessed macular ischemia, time to the first treatment, and the relationship of these with BCVA.RESULTS:
Mean BCVA (log MAR) was significantly improved from 0.67 +/- 0.43 at baseline to 0.30 +/- 0.30 at 48 months (p 6 weeks) treatment groups in BCVA and mean change in BCVA after 48 months. There was statistically significant (p 6 weeks) treatment groups with macular ischemia in BCVA after 48 months.CONCLUSIONS:
In patients with BRVO, a significant visual improvement was maintained after intravitreal bevacizumab injections, despite the presence of macular ischemia. Early treatment (within 6 weeks) is more effective for maintaining and improving visual acuity. Similar results in the macular ischemia group confirmed the importance of early treatment.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Veia Retiniana
/
Retinaldeído
/
Oclusão da Veia Retiniana
/
Acuidade Visual
/
Estudos Retrospectivos
/
Seguimentos
/
Tomografia de Coerência Óptica
/
Bevacizumab
/
Isquemia
Tipo de estudo:
Estudo observacional
/
Estudo prognóstico
Limite:
Humanos
Idioma:
Coreano
Revista:
Journal of the Korean Ophthalmological Society
Ano de publicação:
2014
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS